ResearcherGerman Cancer Research CenterNo recent work listed

Rūta Veinalde

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9190-5574; OpenAlex author ID A5000393521. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2022: 1 paper

Papers 1

Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. Co-author DOI 10.3389/fimmu.2022.1096162 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christine E. Engeland · 1 shared paper, 2022 · strength 0.14
- Paper Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity i… DOI 10.3389/fimmu.2022.1096162 ↗
Claudia R. Ball · 1 shared paper, 2022 · strength 0.14
- Paper Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity i… DOI 10.3389/fimmu.2022.1096162 ↗
Guy Ungerechts · 1 shared paper, 2022 · strength 0.14
- Paper Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity i… DOI 10.3389/fimmu.2022.1096162 ↗
Theresa E. Schäfer · 1 shared paper, 2022 · strength 0.14
- Paper Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity i… DOI 10.3389/fimmu.2022.1096162 ↗
Albrecht Stenzinger · 1 shared paper, 2022 · strength 0.14
- Paper Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity i… DOI 10.3389/fimmu.2022.1096162 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.